Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 619 for:    oximeter

Prizma Pulse Oximeter Evaluation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03080688
Recruitment Status : Completed
First Posted : March 15, 2017
Last Update Posted : March 15, 2017
Sponsor:
Information provided by (Responsible Party):
G Medical Innovations Ltd.

Brief Summary:

This study is intended to evaluate performance of the new design sufficiently to support performance claims for an FDA 510K submission or ISO technical file. Specifically:

  • SpO2 value range 70% to 100%
  • 10 or more subjects, at least 3 of dark pigmentation
  • At least 200 data points
  • Meeting the following test required by the 2013 FDA Guidance on Pulse Oximeters - Premarket Notification Submissions and by ISO 80601-2-61 on Pulse Oximeters:
  • 2013 FDA Guidance on Pulse Oximeters - Premarket Notification Submissions:

    • 4.1. ACCURACY OF PULSE OXIMETERS
    • 4.1.1 IN VIVO TESTING FOR SPO2 ACCURACY UNDER LABORATORY CONDITIONS
  • ISO 80601-2-61:2011 Annex EE.2 and clause 201.12.1.101.2

    • 201.12.1.101 SpO2 accuracy of pulse oximeter equipment
    • 201.12.1.101.2 Determination of SpO2 accuracy

Condition or disease Intervention/treatment
Oxygen Deficiency Device: Prizma Oxygen Saturation Measurement

Detailed Description:

The device under test was the Prizma which is a phone cover biometric device that includes reflectance oximetry. This device is a spot checker that requires the patient to hold their finger on the sensor during the measurement. The subjects were asked not to move during the study. In order to get consistent measurements the fingers were taped to the test device. The tape acted mainly as a reminder, and there were some problems with finger movement. A radial arterial cannula was placed in either the left or right wrist of each subject.

Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1). Each subject had control data taken at the beginning of each experiment, with two control blood samples drawn while breathing room air. Hypoxia was induced to different levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, room air, and carbon dioxide. Oxyhemoglobin saturation was reduced to a series of targets and stabilized at the plateau value. Each plateau level of oxyhemoglobin saturation was maintained for at least 30 seconds. Two arterial blood samples were then obtained, approximately 30 seconds apart. A total of 24 samples were obtained per subject. Data were recorded by Bickler-Ye lab and provided for analysis.


Layout table for study information
Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prizma Pulse Oximeter Evaluation
Actual Study Start Date : April 15, 2016
Actual Primary Completion Date : April 15, 2016
Actual Study Completion Date : April 16, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Group/Cohort Intervention/treatment
Prizma
Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
Device: Prizma Oxygen Saturation Measurement

A radial arterial cannula was placed in either the left or right wrist of each subject.

Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1).





Primary Outcome Measures :
  1. Blood oxygen saturation [ Time Frame: 2 days ]
    Comparison of Measurements: Prizma Device versus Gold Standard



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Selection of patients, both male and female, who meet the eligibility criteria (see below)
Criteria

Inclusion Criteria:

  • Both male and female subjects
  • Healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile below.
  • Meeting the demographic requirements listed above.

Exclusion Criteria:

  • Smokers or individuals exposed to high levels of carbon monoxide that result in carboxyhemoglobin levels over 3% as tested by the BYL.
  • Subjects who would be placed under medical risk under the desaturation profile listed below.
  • Significant arrhythmia
  • Age below 21 or over 50
  • Pregnant women

Layout table for additonal information
Responsible Party: G Medical Innovations Ltd.
ClinicalTrials.gov Identifier: NCT03080688     History of Changes
Other Study ID Numbers: BYL20160415
First Posted: March 15, 2017    Key Record Dates
Last Update Posted: March 15, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoxia
Signs and Symptoms, Respiratory
Signs and Symptoms